The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure

This study has been completed.
Sponsor:
Information provided by:
Istanbul University
ClinicalTrials.gov Identifier:
NCT00978653
First received: September 14, 2009
Last updated: September 21, 2009
Last verified: September 2009

September 14, 2009
September 21, 2009
April 2008
March 2009   (final data collection date for primary outcome measure)
Endothelial function improvement with uric acid lowering treatment [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00978653 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease

In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
  • Hyperuricemia
  • Chronic Kidney Disease
Drug: allopurinol
150 mg once a day
Other Name: urikoliz
Experimental: Allopurinol
Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
Intervention: Drug: allopurinol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
May 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Laboratory finding of hyperuricemia
  • Patients between ages of 18 and 60 years
  • Non-diabetic patients
  • Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion Criteria:

  • Low (< 20 ml/min/1.73 m2) creatinine clearance,
  • Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
  • Patients taking urate lowering medication (allopurinol and probenecid)
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT00978653
200931386
No
Alaattin Yildiz, Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Istanbul University
Not Provided
Principal Investigator: Berna Yelken, MD Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Principal Investigator: Yasar Caliskan Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Study Director: Alaattin Yildiz, Prof, MD Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Principal Investigator: Numan Gorgulu, MD Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Istanbul University
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP